Premium
Clinical efficacy of a new 30‐min algorithm for transurethral microwave thermotherapy: initial results
Author(s) -
De La Rosette J.J.M.C.H.,
Francisca E.A.E.,
Kortmann B.B.M.,
Floratos D.L.,
Debruyne F.M.J.,
Kiemeney L.A.L.M.
Publication year - 2000
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1046/j.1464-410x.2000.00732.x
Subject(s) - medicine , lower urinary tract symptoms , international prostate symptom score , urology , nomogram , adverse effect , hyperplasia , prostate , surgery , cancer
Objective To assess the efficacy of a new 30‐min algorithm for high‐energy transurethral microwave thermotherapy (TUMT, Prostasoft 3.5) in the treatment of men with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia. Patients and methods A total of 108 men (mean age 66 years) with bothersome LUTS were treated with the new TUMT protocol. All patients were evaluated using a standard assessment at baseline, 6, 12, 26 and 52 weeks after TUMT. The evaluation included the assessment of objective and subjective outcome measures, with a urodynamic evaluation using pressure‐flow analysis, and the occurrence of adverse events. Results The treatment was well tolerated. In general, the International Prostate Symptom Score improved from a mean of 20.0 at baseline to a mean of 9.3 at 6 months after treatment. The maximum urinary flow improved from 9.4 mL/s to 14.6 mL/s at 6 months. The mean duration of catheterization was 17.9 days. The urodynamic evaluation showed a change from the obstructed to the equivocal zone on the Abrams–Griffith nomogram. There were no serious complications. Urgency and frequency were the most frequent side‐effects after treatment; these all resolved within 3 months. Conclusion High‐energy TUMT using the new high‐dose Prostasoft 3.5 protocol appears to be a safe and effective treatment. The faster procedure improves the tolerance of the treatment. The subjective and objective improvements were significant and the treatment‐related morbidity low. A longer follow‐up is needed to assess the durability of this new treatment protocol.